申请人:Nippon Zoki Pharmaceutical Co., Ltd.
公开号:US04647574A1
公开(公告)日:1987-03-03
The present invention relates to novel hydantoin derivatives represented by the general formula (I) and pharmaceutical compositions containing them as an active ingredient. ##STR1## In the formula (I), X is hydrogen or a group having the formula --OR.sub.4, and each of R.sub.1, R.sub.2, R.sub.3 and R.sub.4, which may be the same or different, is hydrogen, an alkyl group or a cycloalkyl group. Hydantoin derivatives and pharmaceutically acceptable salts thereof of the present invention have excellent hypoglycemic, hypolipidemic and diuretic effects, as well as low toxicity and great safety. Therefore, the compounds of the present invention are not only useful as antidiabetics but also as drugs for hyperlipidemia.
本发明涉及一种新颖的咪唑烷二酮衍生物,其通式表示为(I),以及含有它们作为活性成分的药物组合物。在式(I)中,X为氢或具有式--OR.sub.4的基团,而R.sub.1、R.sub.2、R.sub.3和R.sub.4中的每一个(可能相同也可能不同)为氢、烷基或环烷基。本发明的咪唑烷二酮衍生物及其药用盐具有出色的降糖、降脂和利尿效果,毒性低、安全性高。因此,本发明的化合物不仅可用作抗糖尿病药物,也可用作高脂血症药物。